Immu-Mela is an open-access resource for interactive exploration of a variety of known and novel genomic signatures predictive of immunotherapy response across multiple datasets in melanoma.
TP53 mutation is a critical driver mutation that affects the carcinogenesis and prognosis of patients with pancreatic cancer (PC). Currently, there is no driver mutation-derived signature based on TP5
(A) High signature score correlates with Ktrans improvement in the treatment arm and Ktrans deterioration in the placebo arm. Scatter plots show baseline and treatment adjusted 14-week change in log K
